

Date: May 29, 2026

To, National Stock Exchange of India Limited, “Exchange Plaza”, 5th Floor, Plot No. C/1, G Block, Bandra- Kurla Complex Bandra (East), Mumbai – 400 051	To, BSE Limited, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400 001
Scrip Name: GLENMARK	Scrip Code: 532296
ISIN: INE935A01035	ISIN: INE935A01035
Our Reference No. 11/26-27	Our Reference No. 11/26-27

Dear Sir/ Madam,

**Sub.: Intimation of the Schedule of Analyst / Institutional Investors Meeting**

In accordance with the applicable requirements and regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other applicable Regulations, we would like to inform you that the Company will host “Glenmark Annual Investor Day 2026” as per schedule given hereunder:

Day & Date	<u>Analyst / Institutional Investors Meeting</u>	Venue	Mode of Meeting	Group/ one-on- one
Tuesday, June 09, 2026	Glenmark Annual Investor Day 2026	Mumbai	Physical & Virtual	Group of Investors/ Analysts

*Note: The schedule of the aforesaid meeting is subject to change. The changes may happen due to exigencies on the part of Investors / Company etc.*

The investor presentation shall be made available before the event on the Stock Exchanges and on the website of the Company [www.glenmarkpharma.com](http://www.glenmarkpharma.com). The discussion will be based on the financial and operational performance of the Company as published in the investor presentation/ Investor updates, which has been submitted with the stock exchanges and has also been uploaded on the website of the Company.

**Glenmark Pharmaceuticals Limited**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)

Pursuant to regulation 46 (2) of the Listing Regulations, aforesaid information shall be disclosed on the website of the Company viz. [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Kindly take the above information on your record.

Thanking you,

Yours faithfully,

**For Glenmark Pharmaceuticals Limited**

**Harish Kuber**

**Company Secretary & Compliance Officer**